Results 31 to 40 of about 885,175 (334)

Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling

open access: yesScientific Reports, 2017
Malignant melanoma, characterized by its ability to metastasize to other organs, is responsible for 90% of skin cancer mortality. To investigate alterations in the cellular metabolome and lipidome related to melanoma metastasis, gas chromatography-mass ...
Hye-Youn Kim   +5 more
doaj   +1 more source

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

open access: yesNature Medicine, 2019
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized.
David Liu   +35 more
semanticscholar   +1 more source

Black Pleural Effusion: A Unique Presentation of Metastatic Melanoma

open access: yesCase Reports in Oncology, 2015
Metastatic melanoma is a rare form of skin cancer, but one that comes with a high mortality rate. Pulmonary involvement is frequently seen in metastatic melanoma with only 2% of malignant melanoma patients with thorax metastasis presenting with pleural ...
Akansha Chhabra   +4 more
doaj   +1 more source

Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma

open access: yesClinical and Translational Medicine, 2021
Background 1q21.3 amplification, which is frequently observed in metastatic melanoma, is associated with cancer progression. Interleukin enhancer‐binding factor 2 (ILF2) is located in the 1q21.3 amplified region, but its functional role or contribution ...
Xiaoqing Zhang   +7 more
doaj   +1 more source

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

open access: yesNature Medicine, 2019
Immune checkpoint blockade (ICB) of PD-1 and CTLA-4 to treat metastatic melanoma (MM) has variable therapeutic benefit. To explore this in peripheral samples, we characterized CD8+ T cell gene expression across a cohort of patients with MM receiving anti-
Benjamin P. Fairfax   +14 more
semanticscholar   +1 more source

Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts

open access: yesCell Reports, 2016
The high rate of metastasis and recurrence among melanoma patients indicates the existence of cells within melanoma that have the ability to both initiate metastatic programs and bypass immune recognition.
Michael Ngo   +8 more
doaj   +1 more source

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

open access: yesThoracic Cancer, 2022
Malignant melanoma is the most aggressive skin cancer that originates from melanocytes. Primary or metastatic pleural melanoma shares clinical and imaging characteristics with primary pleural tumors, such as pleural mesothelioma.
Clara So   +4 more
doaj   +1 more source

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. [PDF]

open access: yesPLoS ONE, 2015
Uveal melanoma is the most common malignancy of the adult eye. The overall mortality rate is high because this aggressive cancer often metastasizes before ophthalmic diagnosis.
John W Crabb   +6 more
doaj   +1 more source

Transcription analysis in the MeLiM swine model identifies RACK1 as a potential marker of malignancy for human melanocytic proliferation

open access: yesMolecular Cancer, 2008
Background Metastatic melanoma is a severe disease. Few experimental animal models of metastatic melanoma exist. MeLiM minipigs exhibit spontaneous melanoma. Cutaneous and metastatic lesions are histologically similar to human's.
Vincent-Naulleau Silvia   +8 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy